Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6985933 | 0.86 | CYP11B1 (0.51) | CYP11B1CYP11B2NAMPTKMT2ASMN1; SMN2 | |
| SCHEMBL6981925 | 0.85 | NAMPT (0.50) | CYP11B1CYP11B2NAMPTKMT2ASMN1; SMN2 | |
| SCHEMBL6988934 | 0.77 | CYP11B1 (0.50) | CYP11B1CYP11B2NAMPTKMT2ASMN1; SMN2 | |
| SCHEMBL7163637 | 0.77 | NAMPT (0.46) | CYP11B1CYP11B2NAMPTKMT2ASMN1; SMN2 | |
| SCHEMBL6990458 | 0.76 | CSF1R (0.44) | CYP11B1CYP11B2NAMPTKMT2AMEN1 | |
| SCHEMBL6988180 | 0.75 | NAMPT (0.51) | NAMPTKMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL6985929 | 0.75 | ABCC9 (0.58) | CYP11B1CYP11B2NAMPTKMT2ASMN1; SMN2 | |
| SCHEMBL6981921 | 0.75 | ABCC9 (0.64) | CYP11B1CYP11B2NAMPTKMT2ASMN1; SMN2 | |
| SCHEMBL4024804 | 0.75 | FLT4 (0.47) | CYP11B1CYP11B2NAMPTKMT2AMEN1 | |
| SCHEMBL6986333 | 0.74 | MEN1 (0.48) | KMT2ASMN1; SMN2MEN1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358160-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | claimed |
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | claimed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | claimed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1358160-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | disclosed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165264-A1 | Aminal diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | CYP11B1 364/4885CYP11B2 615/4885NAMPT 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.